



Australian Government
Department of Health and Aged Care
Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:		406950	Eagle MAG Restore Tablets
ARTG entry for	Medicine Listed		
Sponsor	Integria Healthcare Australia Pty Ltd		
Postal Address	PO Box 4854, EIGHT MILE PLAINS, QLD, 4113 Australia		
ARTG Start Date	28/03/2023		
Product Category	Medicine		
Status	Active		
Approval Area	Listed Medicines		

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . Eagle MAG Restore Tablets

Product Type	Single Medicine Product	Effective Date	23/04/2025
---------------------	-------------------------	-----------------------	------------

Permitted Indications

Antioxidant/Reduce free radicals formed in the body
Helps convert (state food) into energy
Maintain/support energy production
Maintain/support general health and wellbeing
Maintain/support bone health
Aids/assists healthy bone development/growth/building
Helps maintain/supports healthy joint cartilage growth/development/production
Aid/assist healthy red blood cell production
Maintain/support red blood cell health
Maintain/support healthy cardiovascular system function
Maintain/support healthy muscle contraction function
Maintain/support muscle health
Maintain/support muscle function
Maintain/support healthy neuromuscular system/function
Maintain/support muscle relaxation
Maintain/support muscle tone
Aid/assist/helps glucose/sugar/carbohydrate metabolism
Maintain/support (state vitamin/mineral/nutrient) levels in the body when dietary intake is inadequate
Maintain/support (state vitamin/mineral) within normal range when dietary intake is inadequate
Maintain/support nerve conduction
Aid/assist/helps synthesis of neurotransmitters
Decrease/reduce/relieve symptoms of premenstrual tension

Indication Requirements

Label statement: If symptoms persist, talk to your health professional.

Product presentation must not imply or refer to bone disease or disorders e.g. rheumatoid arthritis, juvenile arthritis, debilitating osteoarthritis, osteoporosis.
Note: this requirement is not intended to apply where the indications referring to osteoporosis specified in column 2 of the table in Part 2 of Schedule 1 to this instrument are also used.



Australian Government
Department of Health and Aged Care
Therapeutic Goods Administration

Product presentation must not imply or refer to serious cardiovascular conditions.

Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

If product is indicated for weight loss, label statement: When used in conjunction with a program of reduced intake of dietary calories and increased physical activity.

Product presentation must not imply or refer to bone disease or disorders e.g. rheumatoid arthritis, juvenile arthritis, debilitating osteoarthritis, osteoporosis.

Product presentation must not imply or refer to mental illnesses, disorders or conditions.

Product presentation must not imply or refer to any form of arthritis or osteoarthritis unless qualified as mild.

Product presentation must not imply or refer to serious musculoskeletal or neurological conditions.

Product presentation must not imply or refer to lowering or raising blood sugar/glucose levels from outside of the normal healthy range.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

For practitioner dispensing only.

Vitamins and minerals can only be of assistance if dietary intake is inadequate OR Vitamin and/or mineral supplements should not replace a balanced diet.

If symptoms persist, seek the advice of a healthcare professional.

WARNING - Stop taking this medication if you experience tingling, burning or numbness and see your healthcare practitioner as soon as possible.
[Contains vitamin B6].

Additional Product information

Pack Size/Poison information

Pack Size

Poison Schedule

Components

1 . Formulation 1

Dosage Form Tablet, film coated

Route of Administration Oral

Visual Identification

Active Ingredients

calcium hydrogen phosphate dihydrate	307.32 mg
Equivalent: calcium	70 mg
dibasic potassium phosphate	50.91 mg
Equivalent: potassium	22.4 mg
magnesium amino acid chelate	441 mg
Equivalent: magnesium	85 mg
magnesium phosphate pentahydrate	361.5 mg
Equivalent: magnesium	72.3 mg
manganese amino acid chelate	26.32 mg
Equivalent: manganese	5 mg
pyridoxine hydrochloride	25.56 mg
Equivalent: pyridoxine	20.6 mg

Other Ingredients (Excipients)

calcium carbonate
colloidal anhydrous silica
crospovidone
hypromellose
isomalt
magnesium stearate
medium chain triglycerides

Public Summary



Australian Government

Department of Health and Aged Care

Therapeutic Goods Administration

microcrystalline cellulose

povidone

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary